Evidence map›Paper›PMID 30807838›Full record

ArticleBrain, behavior, and immunity2019

Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota.

A T Sougiannis, B N VanderVeen, R T Enos, K T Velazquez, J E Bader, M Carson, I Chatzistamou, M Walla, M M Pena, J L Kubinak and 3 more

Open access · greenAbstract read
In one paragraph

Article in Brain, behavior, and immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 141 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Elevated CCL20 and IL-10 enhance 5-fluorouracil tolerance in colon cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Cancer Cachexia.Advances in experimental medicine and biology · 2025
    Review
  20. Fecal microbial transplants as investigative tools in cancer.American journal of physiology. Gastrointestinal and liver physiology · 2024
    Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

A T SougiannisDepartment of Pathology, Microbiology, & Immunology, School of Medicine, University of South Carolina, SC 29209, USA.
B N VanderVeenDepartment of Exercise Science, School of Public Health, University of South Carolina, SC 29201, USA.
R T EnosDepartment of Pathology, Microbiology, & Immunology, School of Medicine, University of South Carolina, SC 29209, USA.
K T VelazquezDepartment of Pathology, Microbiology, & Immunology, School of Medicine, University of South Carolina, SC 29209, USA.
J E BaderDepartment of Pathology, Microbiology, & Immunology, School of Medicine, University of South Carolina, SC 29209, USA.
M CarsonDepartment of Pathology, Microbiology, & Immunology, School of Medicine, University of South Carolina, SC 29209, USA.
I ChatzistamouDepartment of Pathology, Microbiology, & Immunology, School of Medicine, University of South Carolina, SC 29209, USA.
M WallaDepartment of Chemistry, University of South Carolina, SC 29201, USA.
M M PenaDepartment of Biology, University of South Carolina, SC 29201, USA.
J L KubinakDepartment of Pathology, Microbiology, & Immunology, School of Medicine, University of South Carolina, SC 29209, USA.
M NagarkattiDepartment of Pathology, Microbiology, & Immunology, School of Medicine, University of South Carolina, SC 29209, USA.
J A CarsonCollege of Health Professions, University of Tennessee Health Sciences Center, Memphis, TN 38163, USA.
E A MurphyDepartment of Pathology, Microbiology, & Immunology, School of Medicine, University of South Carolina, SC 29209, USA. Electronic address: angela.murphy@uscmed.sc.edu.
University of South Carolina · USUniversity of Tennessee Health Science Center · US

Funding

Targeting early ceramide elevation in pre-symptomatic eczemaP20GM103641 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, PRAKASH S · 2012 to 2023
$20.7M
TISSUE BIOREPOSITORY COREP30GM103336 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BERGER, FRANKLIN G. · 2013 to 2017
$5.4M
The effects of Ojeok-san on neuro-immune interactions in cancer-induced visceral painR00AT009206 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI VELAZQUEZ, KANDY T · 2019 to 2021
$747k
Targeting macrophages to reduce colorectal cancer: Impact of metabolic reprogrammingK00CA234920 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BADER, JACKIE · 2019 to 2022
$377k
The effects of Ojeok-san on neuro-immune interactions in cancer-induced visceral painK99AT009206 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI VELAZQUEZ, KANDY T · 2017 to 2018
$199k
Enhancing the efficacy of 5 fluorouracil using emodin as a complementary therapeuticF31AT009820 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI SOUGIANNIS, ALEXANDER THEODORE · 2018 to 2020
$98k
Targeting macrophages to reduce colorectal cancer: Impact of metabolic reprogrammingF99CA234920 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BADER, JACKIE · 2018 to 2018
$36k
NCCIH NIH HHS F31 AT009820NCCIH NIH HHS K99 AT009206NCCIH NIH HHS R00 AT009206NCI NIH HHS F99 CA234920NCI NIH HHS K00 CA234920NIGMS NIH HHS P20 GM103641NIGMS NIH HHS P30 GM103336
6 · The paper itself

Abstract

Emerging evidence suggests that gut microbiota may influence the response to chemotherapy. We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response. 50 C57BL/6 were randomized into four groups; Control + Vehicle (n = 10), Control + 5FU (n = 10), AOM/DSS + Vehicle (n = 15), and AOM/DSS + 5FU (n = 15). CRC was induced chemically by a single 10 mg/kg injection of azoxymethane (AOM) followed by two cycles (2% and 1%) of dextran sodium sulfate (DSS). Mice were then treated with 3 cycles of vehicle or 5FU (cycle 1: 40 mg/kg, cycle 2 + 3: 20 mg/kg). Functional tests (grip strength and run-to-fatigue) were performed prior to 5FU treatment (baseline) and at the completion of the second cycle of 5FU. Following the third 5FU cycle, mice were euthanized and the colon was evaluated for expression of inflammatory genes using RT-qPCR and stool samples were profiled using 16S rRNA sequencing. A second experiment used fecal microbiota transplantation from 5FU treated mice to control mice (n = 10-15/group) to determine whether 5FU associated changes in the microbiota could influence functional measures and colon inflammation. 5FU reduced grip strength (p < 0.05) and caused a trending decrease in run-to-fatigue performance in cancer mice (p = 0.06). Select intestinal inflammatory genes were significantly elevated with 5FU treatment and this was further exacerbated with cancer (p < 0.05). Microbiota analysis revealed increased dissimilarity and alterations in bacterial taxonomy in 5FU and AOM/DSS-treated mice (p < 0.05). Fecal transplant from 5FU treated mice reduced functional performance (p < 0.05) and altered select colon inflammatory markers (p < 0.05). This study provides evidence of an effect of 5FU on inflammatory responses and functional measures in a mouse model of CRC and suggests that gut microbes may play a role in some, but not all, 5FU related perturbations.

Indexed as

AnimalsAzoxymethaneColitisColonColonic NeoplasmsColorectal NeoplasmsDextran SulfateDisease Models, AnimalFecal Microbiota TransplantationFluorouracilGastrointestinal MicrobiomeInflammationMaleMiceMice, Inbred C57BLAzoxymethaneDextran SulfateFluorouracil5-FluorouracilChemotherapyColorectal cancerFecal transplantInflammationMicrobiotaToxicity

Identifiers

PMID30807838
PMCPMC6660349
OpenAlexW2917067829

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.